Dr. Moore, a former United States Assistant Surgeon General, provides strategic planning for AREV’s nutritional and drug discovery platforms, as Chairman of the Scientific Advisory Board. Dr. Moore is a member of the board of advisers of the Institute of Human Virology (IHV) and the board of directors of the Global Virus Network associated with IHV, University of Maryland Medical Center. IHV is the first research institute in the U.S. to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments; its 80 faculty members contribute to research on pandemic pathogens, ranging from COVID-19 to HIV.
Dr. Moore served with the United States Department of Health and Human Services (HHS) and was responsible for the last 12 years of his career for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs for resource-challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service entering with the U.S. National Institutes of Health (NIH) and rising to the rank to Rear Admiral. Dr. Moore worked at the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming senior epidemiologist within the National Institute for Occupational Safety and Health of the U.S. Centers for Disease Control and Prevention (CDC), where he also served as an epidemic intelligence service officer.
Dr. Moore has conducted clinical research on infectious diseases, has evaluated the safety and effectiveness of medical devices, and has conducted relevant epidemiological research on the utilization experience and human health effects of medical devices and radiation. Dr. Moore served on the Fogarty International Center advisory board of directors, NIH, from 2009 to 2013. He served on the alumni board of directors for the school of public health, University of Michigan, from 1987 to 1993. Dr. Moore served on the dean's alumni council, Bloomberg School of Public Health, at Johns Hopkins University, from 1998 to 2002. He has also served as an affiliate associate professor of environmental health for the University of Washington, Seattle, from 1994 to 2003, and as an adjunct professor of epidemiology for the Medical University of Southern Africa, Pretoria, South Africa, from 1999 to 2002. He served on the board of directors for the Africa Center for Health and Human Security, at George Washington University, from 2006 to 2009.
Dr. Dhanabalan advises AREV on product development and formulation. She is the founder and CEO of Global Health & Hygiene Solutions LLC, whose mission is to promote wellness and prevent illness locally and globally and runs an independent practice at Uplifting Health & Wellness in Cambridge, Massachusetts. Dr. Dhanabalan, a fellow of the American Academy of Family Physicians, graduated from UMDNJ, Newark, New Jersey with her medical degree and trained in family medicine at MUSC in Charleston, South Carolina; she earned her master's degree in public health from Harvard’s School of Public Health in Boston, Massachusetts and continued her training at Harvard in occupational and environmental medicine.
Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences, College of Pharmacy at Oregon State University. Research Interests include: Cancer prevention by dietary antioxidants, and prostate cancer prevention by the carotenoid lycopene. Mass spectrometry-based pharmacological screening of natural products and combinatorial libraries for drug discovery, and high throughput screening to asses drug metabolism, toxicity and bioavailibility.
Dr. Levinson received both his Bachelor of Science in Psychobiology and his Medical Doctorate from the University of Miami. While at the University of Miami, in 1993 Dr. Levinson created and chaired an alternative medicine conference which was integrated into the medical school's curriculum for both students and professors. He also pursued academia as an Assistant Professor in the Department of Psychiatry at Florida International University's College of Medicine. Dr. Levinson has affiliation with: the International AIDS Society (IAS), the International Association of Providers of AIDS Care (IAPAC), the American Academy of HIV Medicine (AAHIVM), and the Infectious Disease Society of America (IDSA).
Dr. Apte specializes in neurology and has an extensive background in research, teaching and consulting in the field of neurological sciences. Dr. Apte's graduate training was at Haffkine Institute in Mumbai, India, The Pasteur Institute in Paris, France, at Harvard Medical School in Boston and at Stanford University in California. His professional appointments have included active staff positions at the VA Medical Center and Valley Memorial Hospital in Livermore, Calif.; ValleyCare Medical Center in Pleasanton, Calif., and directorships with PainCare Medical Clinic, and the Sleep Disorders Center in San Ramon and Pleasanton, Calif. He most recently served as president and CEO of Northern California Physicians Associates Inc. and Alpha Medical Group Inc. (1986 to 1992). He served as president and CEO of ImmunoScience Inc. in Pleasanton, Calif., until 2019. Dr. Apte has authored and co-authored a number of articles for medical journals and has several publications pending.
Dr. Harold Smith is the founder, CEO, and president of OyaGen, Inc., a biotechnology company developing therapeutics for various disease states including HIV and cancer. Dr. Smith is also a tenured professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine, with additional appointments as a professor in genetics and pathology and as a member of the Center for RNA Biology.
Under Dr. Smith leadership, OyaGen has discovered and patented first-in-class lead (Irino-L) that enables innate immunity against HIV as a treatment with curative potential for HIV/AIDS and recently sold patented best-in-class Oya1 as candidate treatment for infections due to Coronavirus, Ebola virus, Lassa virus and Pox virus. In addition, Oyagen’s laboratory, platform technology, and broad technical knowhow has enabled the development of a cancer drug discovery platform based on gene editing enzymes. Oyagen is located in Rochester, New York in a state-of-the-art laboratory within the Rochester BioVenture Center.